Clinical Trials · NCT07889453
Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Enrollment
- 650
- Start date
- Oct 2026
- Locations
- 1 site, Canada
- Primary endpoint
- Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort